Patents by Inventor Joan L. Susko-Parrish

Joan L. Susko-Parrish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • In vitro activation of mammalian oocytes
    Patent number: 6680199
    Abstract: A process of parthenogenic activation of mammalian oocytes which includes increasing intercellular levels of divalent cations in the oocyte; and reducing phosphorylation of cellular proteins in the oocyte. One method of accomplishing this is by introducing Ca2+free cation, such as ionomycin, to the oocyte and then preventing phosphorylation of the cellular proteins within the oocyte by adding a serine-threonine kinase inhibitor, such as 6-dimethylaminopurine (DMAP).
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: January 20, 2004
    Assignee: Infigen, Inc.
    Inventors: Joan L. Susko-Parrish, David L. Northey, M. Lorraine Leibfried-Rutledge, Steven L. Stice
  • Parthenogenic oocyte activation
    Publication number: 20010047520
    Abstract: A process of parthenogenic activation of mammalian oocytes which includes increasing intercellular levels of divalent cations in the oocyte; and reducing phosphorylation of cellular proteins in the oocyte. One method of accomplishing this is by introducing Ca2+ free cation, such as inomycin, to the oocyte and then preventing phosphorylation of the cellular proteins within the oocyte by adding a serine-threonine kinase inhibitor, such as 6-dimethylaminopurine (DMAP).
    Type: Application
    Filed: February 27, 2001
    Publication date: November 29, 2001
    Inventors: Joan L. Susko-Parrish, David L. Northey, M. Lorraine Leibfried-Rutledge, Steven L. Stice
  • Parthenogenic oocyte activation
    Patent number: 6194202
    Abstract: A process of parthenogenic activation of mammalian oocytes which includes increasing intracellular levels of divalent cations in the oocyte; and reducing phosphorylation of cellular proteins in the oocyte. One method of accomplishing this is by introducing Ca2+ free cation, such as ionomycin, to the oocyte and then preventing phosphorylation of the cellular proteins within the oocyte by adding a serine-threonine kinase inhibitor, such as 6-dimethylaminopurine (DMAP).
    Type: Grant
    Filed: March 4, 1996
    Date of Patent: February 27, 2001
    Assignee: Infigen, Inc.
    Inventors: Joan L. Susko-Parrish, David L. Northey, M. Lorraine Leibfried-Rutledge, Steven L. Stice
  • Parthenogenic oocyte activation
    Patent number: 6077710
    Abstract: A process of parthenogenic activation of mammalian oocytes which includes increasing intracellular levels of divalent cations in the oocyte; and reducing phosphorylation of cellular proteins in the oocyte. One method of accomplishing this is by introducing Ca.sup.2+ free cation, such as ionomycin, to the oocyte and then preventing phosphorylation of the cellular proteins within the oocyte by adding a serine-threonine kinase inhibitor, such as 6-dimethylaminopurine (DMAP).
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: June 20, 2000
    Assignee: Infigen, Inc.
    Inventors: Joan L. Susko-Parrish, David L. Northey, M. Lorraine Leibfried-Rutledge, Steven L. Stice
  • Parthenogenic bovine oocyte activation
    Patent number: 5843754
    Abstract: A process of parthenogenic activation of mammalian oocytes which includes increasing intercellular levels of divalent cations in the oocyte; and reducing phosphorylation of cellular proteins in the oocyte. One method of accomplishing this is by introducing Ca.sup.2+ free cation, such as ionomycin, to the oocyte and then preventing phosphorylation of the cellular proteins within the oocyte by adding a serine-threonine kinase inhibitor, such as 6-dimethylaminopurine (DMAP).
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: ABS Global, Inc.
    Inventors: Joan L. Susko-Parrish, David L. Northey, M. Lorraine Leibfried-Rutledge, Steven L. Stice
  • Parthenogenic oocyte activation
    Patent number: 5496720
    Abstract: A process of parthenogenic activation of mammalian oocytes which includes increasing intercellular levels of divalent cations in the oocyte; and reducing phosphorylation of cellular proteins in the oocyte. One method of accomplishing this is by introducing Ca.sup.2+ free cation, such as ionomycin, to the oocyte and then preventing phosphorylation of the cellular proteins within the oocyte by adding a serine-threonine kinase inhibitor, such as 6-dimethylaminopurine (DMAP).
    Type: Grant
    Filed: February 10, 1993
    Date of Patent: March 5, 1996
    Inventors: Joan L. Susko-Parrish, David L. Northey, M. Lorraine Leibfried-Rutledge, Steven L. Stice